Sling Therapeutics Raises $123 Million for Thyroid Eye Disease Drug
Sling Therapeutics has raised $123 million in a Series C financing to advance linsitinib, an oral drug being developed for thyroid eye disease (TED).
The financing was led by…
Read More...
Read More...
